Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

PMID:28495807
Larkin J , Chmielowski B , Lao CD , Hodi FS , Sharfman W , Weber J , Suijkerbuijk KPM , Azevedo S , Li H , Reshef D , Avila A , Reardon DA
The oncologist
Despite unprecedented efficacy across multiple tumor types, immune checkpoint inhibitor therapy is associated with a unique and wide spectrum of immune-related adverse events (irAEs), including neurologic events ranging from mild headache to potentially life-threatening encephalitis. Here, we summarize neurologic irAEs associated with nivolumab and ipilimumab melanoma treatment, present cases of treatment-related encephalitis, and provide practical guidance on diagnosis and management.


Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved